Dr David Khoury (Team Lead and Scientia Fellow – Translational Analytics Group, Kirby Institute, UNSW) is an interdisciplinary researcher who has pioneered statistical and modelling approaches to address critical questions in infection and immunity. He holds an NHMRC Investigator Grant (EL2), and his research focuses on using quantitative methods to translate basic science research into actionable evidence to guide drug and vaccine development, assessment and deployment decisions. David's research approach integrates evidence synthesis, experimental data and modelling, to deliver a coherent understanding of infection, treatment and immunity. He has provided key evidence to progress vaccine and drug development efforts for both established and emerging pathogens.

Since completing his PhD at UNSW in 2016, David's research impact has been broad. His work has been cited in >210 policy documents globally, including by the WHO, U.S. Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDC) and the Australian Technical Advisory Group on Immunisation (ATAGI). His expertise is frequently sought by leading health policy organisations including the WHO SAGE Advisory Group and the UK based National Institute for Health and Care Excellence (NICE).

David is recognised for being the first to establish neutralising antibodies as a surrogate of protection from COVID-19, which informed national and international regulatory decisions on vaccine deployment and boosting. He has also innovated the way we assess new drugs for malaria leading to multiple industry partnerships (including GSK, Zydus-Calida and Merck) and a formal consultancy role with the Gates-funded Medicines for Malaria Venture (2020-23). David has made major contributions to vaccine policy to combat the Mpox, his work has established the only known association between an immune response and protection against mpox after vaccination, and has informed international vaccination policy.